Elsevier Oncology posted on LinkedIn:
“From the Journal of Thoracic Oncology’s Editor’s Choice collection: compelling phase 1 data in NSCLC therapy.
Han B et al. present findings on Asandeutertinib’s safety, pharmacokinetics, and efficacy in advanced EGFR-mutated NSCLC.”
Title: Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC: A Phase 1 Dose-Escalation and Dose-Expansion Study
Authors: Baohui Han, Jie Liu, Lin Wu, Yanqiu Zhao, Wei Zhang, Bolin Chen, Jianbo He, Jianhua Shi, Yanqing Liu, Zhe Zhang, Xiugui Chen, Yusheng Wu
More posts featuring Lung Cancer.